Literature DB >> 28561377

Country-wide seroprevalence studies on Crimean-Congo hemorrhagic fever and hantavirus infections in general population of Bulgaria.

Iva Christova1, Elitsa Panayotova1, Iva Trifonova1, Evgenia Taseva1, Teodora Hristova1, Vladislava Ivanova1.   

Abstract

Crimean-Congo hemorrhagic fever (CCHF) and hantavirus infections are the two viral hemorrhagic fevers spread in Europe. To test actual circulation of CCHF virus (CCHFV) and hantaviruses in Bulgaria, we conducted country-wide seroepidemiological studies. Serum samples were collected prospectively from 1500 residents of all 28 districts in Bulgaria. CCHFV seroprevalence of 3.7% was revealed. Anamnesis for tick bites, contact with livestock, age over 40 years and residency in Haskovo district were found as risk factors. The highest CCHFV seroprevalence was observed in the known endemic districts in southeastern Bulgaria: Haskovo (28%) and Yambol (12%). Reactive samples were found in residents of 20 of the 28 districts in Bulgaria. In comparison with the previous studies, the data presented indicate that CCHFV increased substantially its circulation in the endemic regions and was introduced in many new areas. Hantavirus seroprevalence was based on results of the immunoblot and estimated as 3.1%. Surprisingly, contrary to all available data, Puumala virus seroprevalence rate was 2.3% versus 0.8% of Dobrava-Belgrade virus. Evidence for hantavirus IgG seropositivity was found in residents of 23 of the 28 districts in the country. The first hantavirus seroprevalence study in Bulgaria showed that Puumala virus is probably more wide-spread in the country than Dobrava-Belgrade virus.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Crimean-Congo hemorrhagic fever; hantavirus; hemorrhagic fever with renal syndrome; seroprevalence

Mesh:

Substances:

Year:  2017        PMID: 28561377     DOI: 10.1002/jmv.24868

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Prevalence of Crimean-Congo Hemorrhagic Fever Virus among Livestock and Ticks in Zhambyl Region, Kazakhstan, 2017.

Authors:  Jonathan Bryant-Genevier; Yekaterina Bumburidi; Lilit Kazazian; Victoria Seffren; Jennifer R Head; Dmitriy Berezovskiy; Bakhytkul Zhakipbayeva; Stephanie J Salyer; Barbara Knust; John D Klena; Cheng-Feng Chiang; Gulfaira Mirzabekova; Kumisbek Rakhimov; Jandar Koekeev; Kanatbek Kartabayev; Seydigapbar Mamadaliyev; Marta Guerra; Curtis Blanton; Trevor Shoemaker; Daniel Singer; Daphne B Moffett
Journal:  Am J Trop Med Hyg       Date:  2022-04-04       Impact factor: 3.707

2.  High seroprevalence for Crimean-Congo haemorrhagic fever virus in ruminants in the absence of reported human cases in many regions of Bulgaria.

Authors:  Iva Christova; Elitsa Panayotova; Martin H Groschup; Iva Trifonova; Simona Tchakarova; Miriam Andrada Sas
Journal:  Exp Appl Acarol       Date:  2018-04-30       Impact factor: 2.132

3.  Sensitive and specific detection of Crimean-Congo Hemorrhagic Fever Virus (CCHFV)-Specific IgM and IgG antibodies in human sera using recombinant CCHFV nucleoprotein as antigen in μ-capture and IgG immune complex (IC) ELISA tests.

Authors:  Petra Emmerich; Angela Mika; Ronald von Possel; Anne Rackow; Yang Liu; Herbert Schmitz; Stephan Günther; Kurtesh Sherifi; Barie Halili; Xhevat Jakupi; Lindita Berisha; Salih Ahmeti; Christina Deschermeier
Journal:  PLoS Negl Trop Dis       Date:  2018-03-26

4.  Determination of Seroprevalence and Risk Factors of Crimean-Congo Haemorrhagic Fever (CCHF) in the Endemic Region in Turkey: A Population-Based Cross-Sectional Study.

Authors:  Rıza Çıtıl; Mücahit Eğri; Yalçın Önder; Fazilet Duygu; Yunus Emre Bulut; Özkan Yaşayancan; Nagehan Yıldız Çeltek; Şafak Şahin
Journal:  J Trop Med       Date:  2021-05-17

5.  Crimean Congo hemorrhagic fever serosurvey in humans for identifying high-risk populations and high-risk areas in the endemic state of Gujarat, India.

Authors:  Devendra T Mourya; Pragya D Yadav; Yogesh K Gurav; Prachi G Pardeshi; Anita M Shete; Rajlaxmi Jain; Dinkar D Raval; Kamlesh J Upadhyay; Deepak Y Patil
Journal:  BMC Infect Dis       Date:  2019-02-01       Impact factor: 3.090

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.